The primary endpoint miss is a clear negative, but the strong subgroup and biomarker signals create a meaningful second chance via FDA Type C meeting. The stock will likely be highly volatile on this mixed data — the market will need to judge whether the FDA accepts an enriched population design. Key catalysts: Type C meeting outcome, final LEVEL-2 protocol details, data presentations at ESC. Traders should watch for buy-the-dip / sell-the-news patterns.
Price Chart
Executive Summary
Tenax Therapeutics (TENX) announced that its Phase 3 LEVEL trial of TNX-103 for PH-HFpEF failed to meet the primary endpoint of improving 6-minute walk distance versus placebo (LS mean difference of +3.5 meters, p=0.63). However, prespecified exploratory subgroup analyses showed a strong treatment effect in patients with higher disease burden, including a +26.3 meter improvement in patients with baseline walk distance below the median of 333 meters (nominal p=0.0112), and a 49% reduction in NT-proBNP in the overall population (nominal p<0.0001). Management will request a Type C meeting with the FDA to discuss an enriched development path forward.
Key Facts
- Phase 3 LEVEL trial of TNX-103 failed to meet the primary endpoint of 6-minute walk distance at Week 12
- LS mean difference vs placebo was +3.5 meters (SE 7.3, p=0.63)
- Prespecified subgroup with baseline 6MWD <333 m showed +26.3 meter improvement (95% CI 6.0, 46.7, nominal p=0.0112)
- NT-proBNP reduced by 49% vs placebo in the overall population (nominal p<0.0001)
- RVSP reduced by 3.5 mmHg vs placebo in the overall population (nominal p=0.0045)
- Baseline 6MWD in the ongoing LEVEL-2 trial will be capped moving forward
- Serious adverse events balanced between arms (10.8% on TNX-103 vs 10.7% on placebo); no new safety signals
- Management to request Type C meeting with FDA and parallel EMA scientific consultation
- 241 patients randomized across 41 sites in US and Canada
- Full results to be presented at ESC Congress 2026 (Aug 28-31, Munich)
Financial Impact
No financial figures reported; company is a development-stage biotech with no revenue
Risk Factors
- FDA may not accept a single-trial enriched-population NDA based on subgroup analyses with nominal p-values
- The primary endpoint failed outright, which creates a high regulatory hurdle
- LEVEL-2 is already ongoing; if the protocol is not materially changed, it may also fail
- Treatment-related adverse events and discontinuations were higher on drug (38.3% vs 17.4% and 8.3% vs 1.7%)
- Pre-revenue clinical-stage biotech with limited cash runway — the filing does not disclose cash position
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341236 |
| Document: d115761d8k.htm | 0001193125-26-341236 |
| Document: d115761dex992.htm | 0001193125-26-341236 |
| Document: 0001193125-26-341236-index-headers.html | 0001193125-26-341236 |
| Document: 0001193125-26-341236-index.html | 0001193125-26-341236 |
| Document: 0001193125-26-341236.txt | 0001193125-26-341236 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.64 (+20.59%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.64 (+2.50%) |
Oct 9, 2026 17d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.64 (−10.38%) |
Oct 8, 2026 18d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.64 (−12.30%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.64 (−13.68%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.64 (−23.00%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.64 (−10.87%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.64 (+19.27%) |
Jul 31, 2026 12w ago | 8-K | $13.70 $13.44 | ▼ −1.90% | ▼ −5.41% | $1.64 (−88.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers